Want to see EXOZ full AI Analyst Report?
EXOZ Stock Chart & Stats
$11.49
--
Market closed
$11.49
--
Day’s Range― - ―
52-Week Range$6.33 - $18.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.40K
Market Cap
$78.71M
Enterprise Value$53.39M
Total Cash (Recent Filing)$1.44M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding9,281,359
10 Day Avg. Volume1,191
30 Day Avg. Volume2,398
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)26.89
Price to Sales (P/S)0.00
P/FCF Ratio-13.69
Enterprise Value/Market Cap0.68
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.65K
Enterprise Value/Ebitda-5.42
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
NIH Phase IIB GrantNon-dilutive NIH funding materially supports R&D for the cannabinoid program, underwriting two years of discovery and preclinical work. This reduces near-term financing pressure for that program, advances platform validation, and increases attractiveness to later-stage partners and licensors.
Platform With Multiple BiosolutionsHaving NCT and a second biosolution (engineered cannabinoid analogs) diversifies scientific risk and addressable markets. Platform-level capabilities enable reuse of expression systems and manufacturing expertise, improving long-term commercialization optionality and partnership appeal across different end markets.
Demonstrated Capital-market AccessRepeated successful offerings show the company can access public capital to fund development and extend runway. For a pre-revenue biotech, sustained market access is a durable operational strength, enabling continued R&D and milestone attainment while management pursues commercialization paths.
Bears Say
Pre-revenue With Widening LossesThe company remains pre-commercial with rapidly expanding net losses, indicating an extended timeline to break-even absent new revenue. Persistent negative earnings erode investor equity and increase dependency on external funding, raising execution risk if R&D fails to produce near-term product revenues.
Consistent Heavy Cash BurnSustained negative operating and free cash flow means the business is structurally funding operations externally. This ongoing burn limits strategic flexibility, compresses time to secure follow-on financing, and makes R&D progress contingent on continual capital raises rather than internal cash generation.
Eroding Equity Base And Dilution RiskA sharply reduced equity base reflects cumulative losses and financing effects, weakening the balance sheet cushion against shocks. Continued reliance on equity raises and complex warrant structures risks ongoing dilution, complicating long-term shareholder value recovery if commercial milestones lag.
eXoZymes News
EXOZ FAQ
What was eXoZymes’s price range in the past 12 months?
eXoZymes lowest stock price was $6.33 and its highest was $18.40 in the past 12 months.
What is eXoZymes’s market cap?
eXoZymes’s market cap is $78.71M.
When is eXoZymes’s upcoming earnings report date?
eXoZymes’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were eXoZymes’s earnings last quarter?
Currently, no data Available
Is eXoZymes overvalued?
According to Wall Street analysts eXoZymes’s price is currently Overvalued.
Does eXoZymes pay dividends?
eXoZymes does not currently pay dividends.
What is eXoZymes’s EPS estimate?
eXoZymes’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eXoZymes have?
eXoZymes has 9,281,359 shares outstanding.
What happened to eXoZymes’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of eXoZymes?
Currently, no hedge funds are holding shares in EXOZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
eXoZymes Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Sold Shares
Worth $15.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-220.64%
Trailing 12-Months
Asset Growth
-65.13%
Trailing 12-Months
Company Description
eXoZymes
Operating within the United States, eXoZymes, Inc. is a pioneering synthetic biochemical enterprise. The company's primary innovation is SimplePath, a sophisticated platform engineered to synthesize a diverse spectrum of chemicals. This output encompasses essential pharmaceuticals, alternative fuels, advanced materials, food additives, and entirely new molecular entities. Integral to its design, the SimplePath platform incorporates distinct modules, each housing one or more enzymes that work synergistically to facilitate specific biocatalytic transformations. The firm was established in 2014 and maintains its corporate headquarters in Monrovia, California.
EXOZ Earnings Call
Q4 2026
0:00 / 0:00
Technical Analysis
Ownership Overview
16.06% Insiders
0.46% Mutual Funds
― Other Institutional Investors
83.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---